Ticker Details
Esperion Therapeutics, Inc. Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C.
IPO Date:	June 26, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$805.76M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.72 | 3.27%
Avg Daily Range (30 D):	$0.04 | 1.87%
Avg Daily Range (90 D):	$0.08 | 2.94%

Institutional Daily Volume
Avg Daily Volume:	1.89M
Avg Daily Volume (30 D):	15.99M
Avg Daily Volume (90 D):	8.59M

Trade Size
Avg Trade Size (Sh.):	226
Avg Trade Size (Sh.) (30 D):	309
Avg Trade Size (Sh.) (90 D):	305

Institutional Trades
Total Institutional Trades:	3,337
Avg Institutional Trade:	$1.78M
Avg Institutional Trade (30 D):	$2.09M
Avg Institutional Trade (90 D):	$1.71M
Avg Institutional Trade Volume:	.15M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.17M
Avg Closing Trade (30 D):	$1.43M
Avg Closing Trade (90 D):	$1.13M
Avg Closing Volume:	137.59K

News

May 7, 2026 @ 1:41 AM Halper Sadeh LLC is Investigating Whether SILA, ES... Source: Halper Sadeh Llc

May 5, 2026 @ 6:56 PM BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Inve... Source: Brodsky & Smith

May 4, 2026 @ 3:25 PM What's Going On With Esperion Therapeutics Stock O... Source: Vandana Singh

May 1, 2026 @ 4:55 PM $HAREHOLDER ALERT: The M&A Class Action Firm Annou... Source: Juan Monteverde, Monteverde & Associates Pc

May 1, 2026 @ 12:27 PM Esperion Stock Pops On Billion-Dollar ARCHIMED Buy... Source: Nabaparna Bhattacharya

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$	$-.1	$.32
Diluted EPS	$	$-.1	$.32
Revenue	$418.24M	$80.1M	$168.45M
Gross Profit
Net Income / Loss	$-7.42M	$-25.2M	$61.83M
Operating Income / Loss	$75.79M	$-6.58M	$85.23M
Cost of Revenue
Net Cash Flow	$-11.69M	$-11.69M	$M
PE Ratio

Splits
Jun 11, 2013	1:7